SEAN SAINT
CEO
BETA BIONICS INC.
WHY:Diabetes device industry veteran. Worked as an engineer at Dexcom and Tandem Diabetes Care. Joined Beta as CEO in 2022.
IN THE NEWS: Took the company public in late January. Originally planned to raise $114.4M, but ended up upsizing to $204M with a market cap of nearly $1B.
NOTABLE: Prior to IPO, the company announced a $60M Series E round for the continued development of and commercialization of its automated insulin delivery system, the iLet Bionic Pancreas, which helps people with Type 1 Diabetes (TID) manage their blood sugar levels.
QUOTABLE: “If insulin is like the gas pedal in your car, then glucagon is the brakes.”
